Home > Rheumatology > ACR 2020 > Osteoarthritis – Novel Developments > Anticoagulation with vitamin K antagonist is associated with risk of knee and hip replacement

Anticoagulation with vitamin K antagonist is associated with risk of knee and hip replacement

Presented By
Dr Priyanka Ballal, Boston University Medical Center, USA
Conference
ACR 2020
In contrast to those with direct oral anticoagulation, patients suffering from osteoarthritis using vitamin-K antagonist warfarin had a higher risk of needing knee or hip replacement in a case-control study. “Currently, we have no disease-modifying treatment available, with joint replacement reserved for end-stage disease,” Dr Priyanka Ballal (Boston University Medical Center, USA) stated concerning osteoarthritis (OA) [1]. She pointed out that vitamin K plays a role in coagulation and that several proteins in bone and cartilage depend on it. “Inadequate levels of vitamin K have been shown to cause abnormal joint tissue mineralisation and contribute to the incidence of OA,” she continued to explain. The current study aimed to find out if antagonising vitamin K by warfarin would increase OA progression. Using data from The Health Improvement Network, a nested case-control study was performed that included 913 patients with knee and...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on